

Investors Relations Presentation

Qatari German Medical Devices

Q1 2021

www.qgmd.com





ace of mind for healthcare professionals

Disclaimer

The following presentation is made only to, and is directed only at, persons to whom such a presentation may lawfully

be communicated (“relevant persons”). Any person who is not a relevant person should not act or rely on this

presentation or any of its contents.

This presentation contains forward-looking statements that are subject to risks and uncertainties,

including statements about QGMD’s beliefs and expectations.

These forward-looking statements are based on assumptions that QGMD has made in light of its experience in

the industry in which it operates, as well as its perceptions of historical trends, current conditions, expected future

developments and other factors which QGMD believes are appropriate under the circumstances.

Prospective investors should understand that these statements are not guarantees of future performance or results.

Due to these factors, QGMD cautions that prospective investors should not place undue reliance on any

forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made.

New risks and uncertainties arise from time-to-time, and it is impossible to predict these events or how they may affect QGMD.

Agenda

- Company Overview

QGMD Production facilities & Machineries

Recognition & Quality Assurance at QGMD

- What we do?

- QGMD News

- Sales Figures

- Financial Highlights

Statement of Comprehensive Income

Company Overview

- QG Medical Devices is one of the leading manufacturers of Medical Devices in the Middle East and the only Manufacturing Company producing syringes and IV cannulas in Qatar. Headquartered in Doha, Qatar.
- QG Medical Devices Co. was established in the year 2000, with collaboration of a German Company to produce high quality medical devices in Qatar; utilizing best of breed technology and machines.
- QG Medical Devices is a Public Listed Company in Qatar Stock Exchange. Top Governmental Organizations are the major Share Holders.





QGMD Production Facilities & Machineries

- QG Medical Devices is equipped with state of art production facility designed by reputable innovative technology providers from Germany, Switzerland and Italy.

What We Do?

QGMD is striving to become a leading medical devices manufacturer in the healthcare industry worldwide, as well as a strong partner in the medical trading and services industry; by continuing to introduce innovative and superior medical devices which guarantee better patient care.

- We strive :
- To introduce cutting edge solutions to the medical devices industry whereby Patient and Medical Staff Care are the core of our innovation
- To provide the international health community with safe, effective, and efficient medical devices of the highest quality.
- To reduce/eliminate (where possible) any potential risks associated with Medical industry .
- To guarantee a continued R&D and investment to produce innovative medical devices for the benefit of our patients and medical staff, and the community as a whole.
- To increase the trading and services lines by acquiring more medical partnership with local, regional and international agencies.
- QGMD is committed to develop innovative products that meet the requirements of the local and international market.



Q Ject[®] 1 ml Syringe



Manufacturing (Q JECT, Q SAFE, Q JECT
Ultra, Q FLOW, Q NEED)



List of Countries Syringes for COVID Vaccine Supplied by QGMD

MoH Romania	Hong Kong	MoH Cyprus
MoH Kuwait	Spain	Australia
Qatar	Argentina	Brazil
Chile	Columbia	Costa Rica
Ecuador	El Salvador	Guatemala
Haiti	Jamaica	Mexico
Nicaragua	Panama	Paraguay
Peru	Uruguay	Venezuela

Syringe for COVID-19 Vaccine

- Supplied Quantity – 65,000,000 pcs of Syringes.

QGMD News

- Supplied Exclusively on time COVID Syringes to **Qatar** & supported Qatar Vaccination Programme.
- Signed Exclusive Distribution Agreement in **Baltic Countries in Europe**.
- **TGA Australia** Registration Done for Syringes.
- Signed Exclusive Distribution Agreement in **Iraq**.
- Signed Exclusive Distribution Agreement in **Iran**.
- Signed Exclusive Distribution Agreement in **Australia**.
- Initiated **US FDA** Registration which is supposed to be finished by end of 2021.
- Products has been Registered in **Yemen**.
- Product Registration stated in **Iraq**.

From Qatar to the World

QGMD - Global Leader in Medical Device Technology



Oman
UNICEF
Papua New Guinea
Iran
Iraq
Libya
Romania
Malaysia
Philippines
Sudan
Pakistan
Cyprus
Switzerland
Poland
South America
(P.A.H.O.)
Uganda

Interim Condensed Financial Statements Review for the Six Months Ended June 30th ,2021

Qatari German Medical Devices

August 15, 2021

www.qgmd.com

By : Abdullah Fuad /Finance Manager /AOM

Balance
Sheet

Equity

Statement
of Changes
in Equity

Investment
by owners

Distribution
to owners

Comprehensive
Income

Losses

STATEMENT OF FINANCIAL POSITION AS AT June 30, 2021

STATEMENT OF FINANCIAL POSITION AS AT June 30, 2021

- Notes
- Working capital increase 130%
- Equity increased +2.8%
- Accumulated losses decreased 1.1%
- Net equity increased +4.3%

	30, June 2021 (QR.) Audited	31, December 2020 (QR.) Audited
ASSETS		
NON-CURRENT ASSETS		
Property, plant, equipment and capital work in progress	113,368,306	115,849,403
Investment properties	12,590,000	12,590,000
Right-of-use assets	92,931	97,578
Intangible assets	10,329,937	10,329,937
Total Non-Current Assets	136,381,174	138,866,918
CURRENT ASSETS		
Inventories	24,251,750	22,308,860
Accounts and other receivables	28,124,836	16,203,300
Cash in hand and at banks	2,439,029	3,035,218
Total Current Assets	54,815,615	41,547,378
Total Assets	191,196,789	180,414,296
	=====	=====
EQUITY AND LIABILITIES		
EQUITY		
Share capital	115,500,000	115,500,000
Legal reserve	30,431,538	30,431,538
Revaluation reserve	11,999,694	11,999,694
Accumulated losses	(125,070,405)	(126,421,406)
Net Equity	32,860,827	31,509,826
NON-CURRENT LIABILITIES		
Employees' end of service benefits	1,054,507	973,031
Loans and borrowings - long term portion	104,968,747	97,755,463
Lease liabilities -long term portion	80,611	90,763
Total Non-Current Liabilities	106,103,865	98,819,257
CURRENT LIABILITIES		
Loans and borrowings - short term portion	21,794,114	28,689,102
Lease liabilities -short term portion	8,604	8,458
Accounts and other payables	15,349,927	6,351,903
Bank overdraft	15,079,452	15,035,750
Total Current Liabilities	52,232,097	50,085,213
Total Liabilities	158,335,962	148,904,470
Total Equity and Liabilities	191,196,789	180,414,296

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (REVIEWED) FOR THE PERIOD ENDED JUNE 30, 2021	Growth Ratio (%)	Six months ended June 30,2021 (QR.) (Review)	Six Months ended June 30,2020 (QR) (Review)
Revenue	<u>+84%</u>	20,850,083	11,353,560
Operating cost (Except Depreciation)		(16,082,555)	(8,269,540)
Gross profit(%)	<u>23%</u>	3,767,528	3,084,020
Other income	<u>+141%</u>	5,424,245	2,251,981
Reversal of Previously recognized impairment losses		-0-	-0-
Selling and distribution expenses		(426,211)	(150,209)
General and administrative expenses	<u>+28%</u>	(3,096,205)	(2,407,670)
Depreciation and amortization		(2,715,532)	(2,743,178)
Operation Profit (Loss) Before Finance cost for the year		3,953,825	34,944
Finance Cost	<u>+129%</u>	(2,602,824)	(1,181,289)
Profit (Loss) for the year		1,351,001	(1,146,345)
Other comprehensive income		-0-	-0-
Total comprehensive (loss) for the period	+218 %	1,351,001	(1,146,345)
		=====	=====
(Loss) per share			
Basic and diluted (loss) per share (QR.)	<u>+220%</u>	0.012	(0.010)
		=====	=====

Thank you

Qatari German Medical Devices
www.qgmd.com